Recent progress in tumor pH targeting nanotechnology

Journal of Controlled Release

Volumn 132, Issue 3, 2008, Pages 164-170

  Lee, Eun Seong ^a,b   Gao, Zhonggao ^a   Bae, You Han ^a  

^a UNIVERSITY OF UTAH   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

Block copolymers; Endosomal pH; Histidine; Micelle; Nanogel; pH double targeting; Sulfonamide; Tumor extracellular pH

Indexed keywords

ENDOSOMAL PH; EXTRACELLULAR PH; HISTIDINE; MULTIDRUG RESISTANCES; NANOCARRIERS; NANOGEL; NANOGELS; POLYMERIC MICELLES; RECENT PROGRESSES; RESEARCH GROUPS; SOLID TUMORS; SULFONAMIDE; TRIGGERED RELEASES; TUMOR CELLS;

ABS RESINS; ACIDS; BLOCK COPOLYMERS; CELL MEMBRANES; COLLOIDS; MICELLES; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY; ONCOLOGY; POLYMERS; POTENTIOMETRIC SENSORS; SULFUR COMPOUNDS;

TUMORS;

COPOLYMER; DOXORUBICIN; NANOCARRIER; NANOGEL; UNCLASSIFIED DRUG;

ACIDITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOSOME; HUMAN; LYSOSOME; MICELLE; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; PH; PH TARGETING; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STRUCTURE ANALYSIS; TARGET ORGAN; TUMOR PH;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; ENDOSOMES; GELS; HUMANS; HYDROGEN-ION CONCENTRATION; LYSOSOMES; MICELLES; NANOPARTICLES; NEOPLASMS; POLYMERS;

EID: 56949105019     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.05.003     Document Type: Review

References (103)

1. Matei D. Novel agents in ovarian cancer. Expert Opin. Investig. Drugs 16 (2007) 1227-1239
2. Gonzalez-Angulo A.M., Morales-Vasquez F., and Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608 (2007) 1-22
3. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Marzola M., Colombo N., and Tredici G. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75 (1995) 1141-1150
4. Carelle N., Piotto E., Bellanger A., Germanaud J., Thuillier A., and Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95 (2002) 155-163
5. Fojo T., and Coley H.M. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin. Breast Cancer 7 (2007) 749-756
6. O'Connor R. The pharmacology of cancer resistance. Anticancer Res. 27 (2007) 1267-1272
7. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transports. Nature 446 (2007) 749-757
8. Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellstrom K.E., and Hellstom I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11531-11536
9. Chaidarun S.S., Eggo M.C., Sheppard M.C., and Stewart P.M. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 135 (1994) 2012-2021
10. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., and Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338 (2005) 284-293
11. Muss H.B., Thor A.D., Berry D.A., Kute T., Liu E.T., Koerner F., Cirrincione C.T., Budman D.R., Wood W.C., Barcos M., and Henderson I.C. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330 (1994) 1260-1266
12. Daniels R.A., Turley H., Kimberley F.C., Liu X.S., Mongkolsapaya J., Ch'En P., Xu X.N., Jin B.Q., Pezzella F., and Screaton G.R. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 15 (2005) 430-438
13. Muller C., Schubiger P.A., and Schibli R. In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 1162-1170
14. Cirstoiu-Hapca A., Bossy-Nobs L., Buchegger F., Gurny R., and Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int. J. Pharm. 331 (2007) 190-196
15. Rapoport N., Gao Z., and Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl. Cancer Inst. 99 (2007) 1095-1106
16. Ponce A.M., Vujaskovic Z., Yuan F., Needham D., and Dewhirst M.W. Hyperthermia mediated liposomal drug delivery. Int. J. Hypertherm. 22 (2006) 205-213
17. Ko J., Park K., Kim Y.S., Kim M.S., Han J.K., Kim K., Park R.W., Kim I.S., Song H.K., Lee D.S., and Kwon I.C. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. J. Control. Release 123 (2007) 109-115
18. Bae Y., Fukushima S., Harada A., and Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. Engl. 42 (2003) 4640-4643
19. Chaudhry A., Carrasquillo J.A., Avis I.L., Shuke N., Reynolds J.C., Bartholomew R., Larson S.M., Cuttitta F., Johnson B.E., and Mulshine J.L. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin. Cancer Res. 5 (1999) 3385-3393
20. Engin K., Leeper D.B., Cater J.R., Thistlethwaite A.J., Tupchong L., and McFarlane J.D. Extracellular pH distribution in human tumours. Int. J. Hypertherm. 11 (1995) 211-216
21. Volk T., Jahde E., Fortmeyer H.P., Glusenkamp K.H., and Rajewsky M.F. pH in human tumour xenografts: effect of intravenous administration of glucose. Br. J. Cancer 68 (1993) 492-500
22. van Sluis R., Bhujwalla Z.M., Raghunand N., Ballesteros P., Alvarez J., Cerdan S., Galons J.P., and Gillies R.J. In vivo imaging of extracellular pH using 1H MRSI. Magn. Reson. Med. 41 (1999) 743-750
23. Ojugo A.S., McSheehy P.M., McIntyre D.J., McCoy C., Stubbs M., Leach M.O., Judson I.R., and Griffiths J.R. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous (19)F and (31)P probes. NMR Biomed. 12 (1999) 495-504
24. Leeper D.B., Engin K., Thistlethwaite A.J., Hitchon H.D., Dover J.D., Li D.J., and Tupchong L. Human tumor extracellular pH as a function of blood glucose concentration. Int. J. Radiat. Oncol. Biol. Phys. 28 (1994) 935-943
25. Tannockand I.F., and Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49 (1989) 4373-4384
26. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., and Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4607-4612
27. Stubbs M., Mcsheehy R.M.J., Griffiths J.R., and Bashford L. Causes and consequences of tumour acidity and implications for treatment. Opinion 6 (2000) 15-19
28. Yamagata M., Hasuda K., Stamato T., and Tannock I.F. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer 77 (1998) 1726-1731
29. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (2000) 1295-1302
30. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., and Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15665-15670
31. Naoraand H., and Montell D.J. Ovarian cancer metastasis: intergrating insights from disparate model organisms. Nat. Rev. Cancer 5 (2005) 355-366
32. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., and Bates S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59 (1999) 8-13
33. Scheffer G.L., Wijngaard P.L.J., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J.L.M., Clevers H.C., and Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1 (1995) 578-582
34. Izquierdo M.A., Shoemaker R.H., Flens M.J., Scheffer G.L., Wu L., Prather T.R., and Scheper R.J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer 65 (1996) 230-237
35. Izquierdo M.A., Scheffer G.L., Flens M.J., Giaccone G., Broxterman H.J., Meijer C.J., van der Valk P., and Scheper R.J. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am. J. Pathol. 148 (1996) 877-887
36. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 65 (2000) 95-106
37. Hynes N.E., and Lane H.A. Erbb receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
38. Henning T., Kraus M., Brischwein M., Otto A.M., and Wolf B. Relevance of tumor microenvironment for progression, therapy and drug development. Anticancer Drugs 15 (2004) 7-14
39. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
40. Shain K.H., and Dalton W.S. Cell adhesion is a key determinant in de novo multidrug resistance (mdr): new targets for the prevention of acquired mdr. Mol. Cancer Ther. 1 (2001) 69-78
41. Kang H.C., and Bae Y.H. pH-tunable endosomolytic oligomers for enhanced nucleic acid delivery. Adv. Funct. Mater. 17 (2007) 1263-1272
42. Kobayashi T., Ishida T., Okada Y., Ise S., Harashima H., and Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 329 (2007) 94-102
43. Mohajer G., Lee E.S., and Bae Y.H. Enhanced intercellular retention activity of novel pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells. Pharm. Res. 24 (2007) 1618-1627
44. Lee E.S., Na K., and Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 103 (2005) 405-418
45. E.S. Lee, Z. Gao, D. Kim, K. Park, I.C. Kwon, Y.H. Bae, Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance: in vivo efficacy, J. Control. Release (in press) doi:10.1016/j.jconrel.2008.04.024.
46. Lee E.S., Kim D., Youn Y.S., Oh K.T., and Bae Y.H. A novel virus-mimetic nanogel vehicle. Angew. Chem. Int. Ed. 47 (2008) 2418-2421
47. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev. 58 (2006) 1655-1670
48. Schwartz M.A., Both G., and Lechene C. The effect of cell spreading on cytoplasmic pH in normal and transformed fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 4525-4529
49. Busa W.B., and Nuccitelli R. Metabolic regulation via intracellular pH. Am. J. Physiol. 246 (1984) R409-R438
50. Simon S.M., Roy D., and Schindler M. Intracellular pH and the control of multidrug resistance. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1128-1132
51. Belhoussine R., Morjani H., Millot J.M., Sharonov S., and Manfait M. Confocal scanning microspectrofluorometry reveals specific anthracycline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells. J. Histochem. Cytochem. 46 (1998) 1369-1376
52. Simon S.M. Role of organelle pH in tumor cell biology and drug resistance. Drug Discov. Today 4 (1999) 32-38
53. Oh K.T., Yin H., Lee E.S., and Bae Y.H. Polymeric nanovehicles for anticancer drugs with triggering release mechanisms. J. Mater. Chem. 17 (2007) 3987-4001
54. Drummond D.C., Zignani M., and Leroux J.C. Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid Res. 39 (2000) 409-460
55. Gerasimov O.V., Boomer J.A., Qualls M.M., and Thompson D.H. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv. Drug Deliv. Rev. 38 (1999) 317-338
56. Shi G., Guo W., Stephenson S.M., and Lee R.J. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/ anionic lipid combinations. J. Control. Release 80 (2002) 309-319
57. Simoes S., Slepushkin V., Duzgunes N., and Pedroso de Lima M.C. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim. Biophys. Acta 1515 (2001) 23-37
58. Tachibana R., Harashima H., Shono M., Azumano M., Niwa M., Futaki S., and Kiwada H. Intracellular regulation of macromolecules using pH-sensitive liposomes and trafficking. Biochem. Biophys. Res. Commun. 251 (1998) 538-544
59. Lee E.S., Shin H.J., Na K., and Bae Y.H. Poly(l-histidine)-PEG block copolymer micelles and pH-induced destabilization. J. Control. Release 90 (2003) 363-374
60. Lee E.S., Na K., and Bae Y.H. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 91 (2003) 103-113
61. Lee E.S., Na K., and Bae Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 5 (2005) 325-329
62. D. Kim, E.S. Lee, K.T. Oh, Z. Gao, Y.H. Bae, Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH, Small (in press).
63. Gao Z.G., Lee D.H., Kim D.I., and Bae Y.H. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J. Drug Target. 13 (2005) 391-397
64. Kim G.M., Bae Y.H., and Jo W.H. pH-induced micelle formation of poly(histidine-cophenylalanine)-block-poly(ethylene glycol) in aqueous media. Macromol. Biosci. 5 (2005) 1118-1124
65. Unpublished results from Bae Lab.
66. Lyer A.K., Khaled G., Fang J., and Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 (2006) 812-818
67. Yin H., Lee E.S., Kim D., Lee K.H., Oh K.T., and Bae Y.H. Physicochemical characteristics of pH-sensitive poly(l-histidine)-b-poly(ethylene glycol)/poly(l-lactic acid)-b-poly(ethylene glycol) mixed micelles. J. Control. Release 126 (2008) 130-138
68. Oh K.T., Lee E.S., Kim D., and Bae Y.H. l-Histidine based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity. Int. J. Pharm 358 (2008) 177-183
69. Sethuraman V.A., and Bae Y.H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release 118 (2007) 216-224
70. Duncan R. Polymer conjugates for tumor targeting and intracytoplasmic delivery. The EPR effect as a common gateway. Pharm. Sci. Technol. Today 2 (1999) 441-449
71. Wong H.L., Bendayan R., Rauth A.M., Xue H.Y., Babakhanian K., and Wu X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 317 (2006) 1372-1381
72. Wang T., Jiang X., Yang D.C., Elliott R.L., and Head J.F. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res. 20 (2000) 799-808
73. Cheng C., Wei H., Shi B.X., Cheng H., Li C., Gu Z.W., Cheng S.X., Zhang X.Z., and Zhuo R.X. Biotinylated thermoresponsive micelle self-assembled from double-hydrophilic block copolymer for drug delivery and tumor target. Biomaterials 29 (2008) 497-505
74. Golstein P.E., Boom A., van Geffel J., Jacobs P., Masereel B., and Beauwens R. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 437 (1999) 652-660
75. Wu C.P., Shukla S., Calcagno A.M., Hall M.D., Gottesman M.M., and Ambudkar S.V. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol. Cancer Ther. 6 (2007) 3287-3296
76. mei Y., Qian F., Wei D., and Liu J. Reversal of cancer multidrug resistance by green tea polyphenols. J. Pharm. Pharmacol. 56 (2004) 1307-1314
77. Chen L.M., Wu X.P., Ruan J.W., Liang Y.J., Ding Y., Shi Z., Wang X.W., Gu L.Q., and Fu L.W. Screening novel, potent multidrug-resistant modulators from imidazole derivatives. Oncol. Res. 14 (2004) 355-362
78. Lee B.D., French K.J., Zhuang Y., and Smith C.D. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol. Res. 14 (2003) 49-60
79. Pierre A., Dunn T.A., Kraus-Berthier L., Leonce S., Saint-Dizier D., Regnier G., Dhainaut A., Berlion M., Bizzari J.P., and Atassi G. In vitro and in vivo circumvention of multidrug resistance by servier 9788, a novel triazinoaminopiperidine derivative. Invest. New Drugs 10 (1992) 137-148
80. Soma C.E., Dubernet C., Bentolila D., Benita S., and Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin a in polyalkylcyanoacrylate nanoparticles. Biomaterials 21 (2000) 1-7
81. van Vlerken L.E., Duan Z., Seiden M.V., and Amiji M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 67 (2007) 4843-4850
82. Kabanov A.V., and Alakhov V.Y. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 1-72
83. Chavanpatil M.D., Patil Y., and Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to p-glycoprotein-mediated drug efflux. Int. J. Pharm. 320 (2006) 150-156
84. Deng W.J., Yang X.Q., Liang Y.J., Chen L.M., Yan Y.Y., Shuai X.T., and Fu L.W. Fg020326-loaded nanoparticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo. Acta Pharmacol. Sin. 28 (2007) 913-920
85. Batrakova E., Lee S., Li S., Venne A., Alakhov V., and Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in mdr cancer cells. Pharm. Res. 16 (1999) 1373-1379
86. Advani R., Lum B.L., Fisher G.A., Halsey J., Chin D.L., Jacobs C.D., and Sikic B.I. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (psc-833), an inhibitor of multidrug resistance. Ann. Oncol. 16 (2005) 1968-1973
87. Wang Y., Yu L., Han L., Sha X., and Fang X. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int. J. Pharm. 337 (2007) 63-73
88. Wu J., Lu Y., Lee A., Pan X., Yang X., Zhao X., and Lee R.J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10 (2007) 350-357
89. Mayer L.D., and Shabbits J.A. The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev. 20 (2001) 87-93
90. Kim S.H., Jeong J.H., Joe C.O., and Park G.T. Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate. J. Control. Release 103 (2005) 625-634
91. Sailaja G., Skountzou I., Quan F.S., Compans R.W., and Kang S.M. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 362 (2007) 331-341
92. Young K.R., McBurney S.P., Karkhanis L.U., and Ross T.M. Virus-like particles: designing an effective AIDS vaccine. Methods 40 (2006) 98-117
93. Liu J., Zeng F., and Allen C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur. J. Pharm. Biopharm. 65 (2007) 309-319
94. Kajiwara E., Kawano K., Hattori Y., Fukushima M., Hayashi K., and Maitani Y. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy. J. Control. Release 120 (2007) 104-110
95. Kommareddy S., and Amiji M. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J. Pharm. Sci. 96 (2007) 397-407
96. Huang M., Wu W., Qian J., Wan D.J., Wei X.L., and Zhu J.H. Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles. Acta Pharmacol. Sin. 26 (2005) 1512-1518
97. Stolnik S., Daudali B., Arien A., Whetstone J., Heald C.R., Garnett M.C., Davis S.S., and Illum L. The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. Biochim. Biophys. Acta 1514 (2001) 261-279
98. Wong H.L., Bendayan R., Rauth A.M., Li Y., and Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 491-504
99. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., and Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 (2006) 6732-6740
100. Kommareddy S., Tiwari S.B., and Amiji M.M. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol. Cancer Res. Treat. 4 (2005) 615-625
101. Vinogradov S.V., Zeman A.D., Batrakova E.V., and Kabanov A.V. Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Release 107 (2005) 143-157
102. Vinogradov S.V., Bronich T.K., and Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 54 (2002) 135-147
103. Oishi M., Hayashi H., Iijima M., and Nagasaki Y. Endosomal release and intracellular delivery of anticancer drugs using pH-sensitive PEGylated nanogels. J. Mater. Chem. 17 (2007) 3720-3725